🇺🇸 ABBV — AbbVie Inc.

Salud Compra
← Volver

Precio actual

294,83 USD

Máx. histórico

294,89

5 días

Caída desde máximo

-0,02%

Rango 52 semanas

190,75 – 298,74

Variación hoy

+3,09%

Cierre anterior

286,00

Rango de hoy

283,32 – 295,40

Volumen hoy

8.408.135

Peor caída histórica

-45,09%

26/01/2018 → 15/08/2019

Recuperado en 477 días

Volatilidad anualizada ⓘ

26,30%

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
51,19 (puede no estar actualizado)
Dividend yield
2,42% (puede no estar actualizado)
Precio objetivo analistas
306,42 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 12 horas
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,9200 USD · Yield: 2,35%
Fecha de pago Importe por participación
15/10/2026 1,7300 USD
15/07/2026 1,7300 USD
15/04/2026 1,7300 USD
16/01/2026 1,7300 USD
15/10/2025 1,6400 USD
15/07/2025 1,6400 USD
15/04/2025 1,6400 USD
15/01/2025 1,6400 USD
15/10/2024 1,5500 USD
15/07/2024 1,5500 USD
12/04/2024 1,5500 USD
12/01/2024 1,5500 USD
12/10/2023 1,4800 USD
13/07/2023 1,4800 USD
13/04/2023 1,4800 USD
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
28/02/2020 82,79 85,71 81,58 85,71 +0,34% 4,99% 18.450.000
27/02/2020 86,19 89,45 84,20 85,42 -3,38% 6,09% 14.184.100
26/02/2020 88,62 91,18 88,19 88,41 -0,86% 3,37% 9.786.900
25/02/2020 93,32 93,46 88,11 89,18 -4,25% 5,73% 11.366.400
24/02/2020 92,17 93,87 92,15 93,14 -1,92% 1,87% 10.705.100
21/02/2020 93,96 95,52 93,38 94,96 +0,77% 2,28% 6.676.000
20/02/2020 93,93 94,39 92,59 94,23 +0,10% 1,92% 5.446.200
19/02/2020 93,77 94,79 93,02 94,14 +0,57% 1,89% 6.349.100
18/02/2020 93,67 94,50 93,26 93,61 -0,47% 1,32% 9.406.300
14/02/2020 95,23 95,30 93,77 94,05 -1,36% 1,61% 11.175.800
13/02/2020 96,85 97,36 95,23 95,35 -2,50% 2,20% 10.613.000
12/02/2020 95,98 97,86 95,71 97,79 +1,86% 2,24% 10.591.000
11/02/2020 95,26 97,08 95,01 96,00 +1,32% 2,17% 10.682.800
10/02/2020 92,36 95,50 92,11 94,75 +2,67% 3,67% 13.998.300
07/02/2020 89,74 92,98 88,88 92,29 +5,86% 4,57% 19.090.300
06/02/2020 87,89 87,96 86,22 87,18 +0,63% 1,98% 7.769.700
05/02/2020 85,06 87,14 84,88 86,63 +2,69% 2,66% 10.020.600
04/02/2020 83,59 84,71 83,59 84,36 +2,50% 1,34% 8.251.500
03/02/2020 81,31 82,60 80,92 82,30 +1,58% 2,07% 10.143.700
31/01/2020 81,54 81,72 80,41 81,02 -0,93% 1,61% 13.870.100
30/01/2020 82,58 82,79 81,18 81,78 -1,71% 1,95% 10.870.000
29/01/2020 83,80 84,00 83,13 83,20 -0,68% 1,04% 5.703.200
28/01/2020 84,99 84,99 83,64 83,77 -0,30% 1,59% 8.614.400
27/01/2020 85,05 85,93 84,00 84,02 +0,57% 2,27% 13.832.000
24/01/2020 85,43 85,48 82,76 83,54 -2,03% 3,18% 13.215.400
23/01/2020 87,05 87,07 84,99 85,27 -2,22% 2,39% 12.266.800
22/01/2020 88,03 88,17 87,15 87,21 -0,89% 1,16% 6.438.900
21/01/2020 87,68 88,53 87,57 87,99 -0,01% 1,09% 13.552.000
17/01/2020 89,13 89,27 87,79 88,00 -1,41% 1,66% 10.122.300
16/01/2020 89,31 89,80 88,92 89,26 +0,00% 0,99% 7.073.200